2026 - Introduced
Rhode Island S.B. 3022
  • Requires health insurers to provide equal access to FDA-approved non-opioid pain medications, eliminating prior authorization and step therapy requirements that currently give opioids a prescribing advantage
2025 - Introduced
South Carolina S.B. 161/H.B. 4165
  • Prohibits preferencing coverage of an opioid prescription treatment over a non-opioid treatment and requires the South Carolina Department of Public Health to create educational materials and guidelines for practitioners about non-opioid alternative treatment options.
2026 - Introduced
South Dakota H.B. 1085
  • Prohibits South Dakota insurers from denying coverage of a prescribed non-opioid medication in favor of an opioid.
  • Bars insurers from imposing stricter utilization controls or higher cost-sharing for non-opioid drugs than for clinically appropriate opioid or narcotic drugs.
2025 - Introduced
South Dakota H.B.1137
  • Ensures FDA-approved non-opioid drugs are not disadvantaged or discouraged with respect to coverage of an opioid on the state preferred drug list.
2026 - Passed
Tennessee H.B. 1741/S.B. 1790
  • Requires a health insurer that offers a policy covering an inmate incarcerated in Tennessee to adopt or amend their preferred drug list so that any FDA-approved non-opioid medication is not disadvantaged or discouraged in coverage compared with an opioid for the treatment or management of pain.
2024 - Passed
Tennessee H.B.37
  • Aligns group health insurance plans providing coverage for state employees with Medicaid non-opioid parity policy, ensuring reimbursement of all FDA-approved non-opioid drugs.
2025 - Passed
Tennessee S.B.2011/H.B.2903
  • Prevents opioids from being preferred over a non-opioid pain medication on TennCare's preferred drug list and makes a non-opioid available immediately upon FDA-approval.
  • Requires state Medicaid departments to ensure prescribers and hospitals are reimbursed for providing non-opioid medications.
  • Prohibits health insurers from denying coverage of a non-opioid prescription drug in favor of an opioid, when prescribed.
2025 - Introduced
Utah S.B. 331
  • Prohibits Medicaid and health insurers from imposing more restrictive or extensive prescription drug utilization management practices for a non-opioid drug than the least restrictive or extensive practice applicable to any opioid.
  • Requires that if Utah Department of Health and Human Services funding is available, pamphlets about opiates should include information about non-opioid drug alternatives.
2026 - Passed
Utah Senate Concurrent Resolution 5
  • Directs the state employee health plan to include at least one clinically appropriate non-opioid prescription alternative for each covered opioid.
  • Prohibits health plan from establishing more restrictive or extensive utilization controls for non-opioid treatments than the least restrictive or extensive utilization control for any opioid.
2026 - Introduced
Virginia H.B. 516
  • Prohibits commercial health insurers from imposing limitations or utilization controls on coverage of a covered FDA-approved non-opioid drug that are more restrictive or less favorable to the enrollee relative to the coverage of an opioid drug for the treatment or management of pain.
2025 - Introduced
Virginia H.B.1765
  • Prohibits health insurers from imposing cost-sharing, prior authorization, step therapy, or other coverage limitations on a covered FDA-approved non-opioid drug.
2024 - Passed
Virginia H.B.699
  • Provides that the Virginia Boards of Medicine, Optometry, Dentistry, and Medicine and Nursing update regulations to require prescribers to document and discuss risks with patients.